
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc demonstrated strong financial growth, achieving a 25% increase in top-line revenue in Q4, supported by a 17% increase in volume and a 5% rise in average selling prices (ASPs), alongside record revenues from patient and digital solutions. The company's fundamentals remain positive, with a 21% revenue growth in Q3, driven by a 13% increase in volume and reiteration of effective cash collection strategies, marking its highest cash collections in history in October. Future revenue projections have been adjusted upward, with estimates for 2026 raised to $433 million and for 2027 to $485 million, reflecting anticipated high return on investment and successful expansion of its sales force to drive further volume growth.
Bears say
CareDx Inc. has projected a negative revenue impact of $7.5 million for 2026, stemming from anticipated changes in Medicare reimbursement policies that may affect 4-8% of its business. Despite a 13% year-over-year growth in Q3'25 testing volumes, overall revenue growth remains sluggish, and the company faces challenges in successfully commercializing new diagnostic solutions, which are critical for its expansion. Additionally, with shares trading at 1.4 to 1.7 times projected revenue estimates for 2026—significantly lower than historical averages—investors are increasingly concerned about the company’s ability to navigate management changes and the competitive diagnostics landscape.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares